[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359209-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359209-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","from-physiology-to-clinical-practice-in-pancreatic-cancer-related-thromboembolism-a-review","From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism - A Review","","Pancreatic cancer (PC) is a highly lethal malignancy associated with the highest rate of thromboembolic complications (TEC) among solid tumors, affecting roughly 5–40% of patients. Tumor and microenvironment interactions drive frequent TEC through procoagulant factor release, proinflammatory signaling, heparanase/podoplanin dysregulation, impaired fibrinolysis, and neutrophil extracellular trap–mediated platelet hyperactivation. Risk models show limited prediction and presentations vary, often making events asymptomatic and difficult to detect. Management of venous thromboembolism (VTE) depends on phase, using LMWH acutely and transitioning to direct oral anticoagulants for long-term care, while recurrence may require dose escalation, switching agents, or considering an inferior vena cava filter. Preventive strategies favor LMWH or UFH, and factor XI inhibitors may offer similar efficacy with improved safety.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/from-physiology-to-clinical-practice-in-pancreatic-cancer-related-thromboembolism-a-review/359209/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/from-physiology-to-clinical-practice-in-pancreatic-cancer-related-thromboembolism-a-review/359209.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How common are thromboembolic complications in pancreatic cancer patients?","Question",{"text":63,"@type":64},"Thromboembolic complications occur in approximately 5–40% of pancreatic cancer patients, with venous thromboembolism being the most common type.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What mechanisms contribute to frequent thromboembolism in pancreatic cancer?",{"text":68,"@type":64},"Tumor and tumor microenvironment factors promote coagulation through tissue factor and proinflammatory cytokine secretion, heparanase and podoplanin overexpression, impaired fibrinolysis, and increased neutrophil extracellular trap formation leading to platelet hyperactivation.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the key treatment options for venous thromboembolism in pancreatic cancer?",{"text":72,"@type":64},"Acute VTE management primarily uses LMWH; for long-term care, LMWH may be replaced with direct oral anticoagulants such as apixaban, edoxaban, or rivaroxaban. For recurrence, options include increasing LMWH dose, switching to an oral anticoagulant, or considering an inferior vena cava filter.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359209,1790211429,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nFrom Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism—A Review  \nMonika Jarowicz 1, Michał Sekuła 1, Wiktor Kociemba 1, Katarzyna Polak 1, Joanna Taczała 1, Kamila Krupa 1, Hanna Miski 1, Marta Fudalej 2,3, Andrzej Deptała 2 and Anna Badowska-Kozakiewicz 2, *  \nAcademic Editor: Daruka Mahadevan  \nReceived: 30 January 2026  \nRevised: 4 March 2026  \nAccepted: 7 March 2026  \nPublished: 10 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Students’ Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland; [monika.jarowicz@uckwum.pl](monika.jarowicz@uckwum.pl) (M.J.);  \n[s082692@student.wum.edu.pl](s082692@student.wum.edu.pl) (M.S.); [s085113@student.wum.edu.pl](s085113@student.wum.edu.pl) (W.K.);  \n[s084636@student.wum.edu.pl](s084636@student.wum.edu.pl) (K.P.); [s085346@student.wum.edu.pl](s085346@student.wum.edu.pl) (J.T.);  \n[kamila.krupa@student.wum.edu.pl](kamila.krupa@student.wum.edu.pl) (K.K.); [s090695@student.wum.edu.pl](s090695@student.wum.edu.pl) (H.M.)  \n2 Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland; [marta.fudalej@wum.edu.pl](marta.fudalej@wum.edu.pl) (M.F.); [andrzej.deptala@wum.edu.pl](andrzej.deptala@wum.edu.pl) (A.D.)  \n3 Department of Oncology, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland  \n* Correspondence: [anna.badowska-kozakiewicz@wum.edu.pl](anna.badowska-kozakiewicz@wum.edu.pl)  \nSimple Summary  \nPancreatic cancer (PC) is a common and highly lethal solid tumor with rising incidence and mortality rates. The most common type of PC is pancreatic ductal adenocarcinoma, which has the highest incidence of thromboembolic complications of all malignant tumors. These events, particularly deep vein thrombosis and pulmonary embolism, are associated with increased mortality during the course of the disease. This review summarizes tumorand microenvironment-driven mechanisms of thromboembolism in PC and highlights key risk factors related to the disease, patient characteristics, and treatment modalities. It also outlines warning signs that require further diagnostic evaluation and summarizes diagnostic methods, treatment options, and preventive measures. Finally, the review identifies deficiencies in the management of thromboembolic complications in PC patients and presents ongoing research aimed at improving patient care.  \nAbstract  \nPancreatic cancer (PC) is a highly lethal malignancy linked to the highest rate of thromboembolic complications (TEC) among all solid tumors. TECs occur in approximately 5–40% of PC patients. The most common type of TEC in PC is venous thromboembolism (VTE) . The mechanisms leading to frequent TEC in PC are complex and involve interactions between tumor-derived procoagulant factors and the prothrombotic tumor microenvironment (TME) . Secretion of tissue factor and proinflammatory cytokines by tumor cells and the TME, overexpression of heparanase and podoplanin, impaired fibrynolysis and increased neutrophil extracellular trap formation lead to platelet hyperactivation resulting in hypercoagulability in PC. Understanding these mechanisms is crucial for identifying risk factors of TEC. Current thromboembolism risk models have limited predictive accuracy, which reduces their clinical usefulness. Identifying patients with thromboembolism is challenging because these events are often asymptomatic and their clinical presentation varies depending on the location of the thrombus. Treatment of VTE in PC depends on the phase of the VTE; in the acute phase, treatment primarily involves LMWH. For long-term management, LMWH may be replaced by direct oral anticoagulants such as apixaban, edoxaban, or rivaroxaban. In cas","cbCaigXsZ3Ngwh2i","https://ap.wps.com/l/cbCaigXsZ3Ngwh2i","pdf",1006021,22,"English","# Introduction\n## Epidemiology and burden of pancreatic cancer-related thromboembolism\n## Types and clinical significance of thromboembolic complications\n# Mechanisms of thromboembolism in pancreatic cancer\n# Risk factors and risk prediction models\n# Clinical presentation and diagnostic approach\n# Treatment strategies and preventive measures\n# Unmet needs and future research directions","[{\"question\":\"How common are thromboembolic complications in pancreatic cancer patients?\",\"answer\":\"Thromboembolic complications occur in approximately 5–40% of pancreatic cancer patients, with venous thromboembolism being the most common type.\"},{\"question\":\"What mechanisms contribute to frequent thromboembolism in pancreatic cancer?\",\"answer\":\"Tumor and tumor microenvironment factors promote coagulation through tissue factor and proinflammatory cytokine secretion, heparanase and podoplanin overexpression, impaired fibrinolysis, and increased neutrophil extracellular trap formation leading to platelet hyperactivation.\"},{\"question\":\"What are the key treatment options for venous thromboembolism in pancreatic cancer?\",\"answer\":\"Acute VTE management primarily uses LMWH; for long-term care, LMWH may be replaced with direct oral anticoagulants such as apixaban, edoxaban, or rivaroxaban. For recurrence, options include increasing LMWH dose, switching to an oral anticoagulant, or considering an inferior vena cava filter.\"}]","From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism - A Review | PDF",1790136418,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db256f17a7222cd869dfa9cbeea55c34.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d12323b3f87725ef4451316836766c7b.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a32ab4f3f905d3364d219613ad929f4.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/148c9110dc0addb41d82131d6c3c381b.webp",980,1385]